Celsion Corporation (NASDAQ:CLSN) up 4% in a week. The company has announced preclinical in vivo studies results demonstrating antibodies production and cytotoxic T-cell response to SARS-CoV-2 spike antigen in immunization of BALB/c mice with Celsion’s next-gen PLACCIUNE DNA vaccine.
Interestingly the SARS-CoV-2 spike antigen antibodies prevented cultured cells infection in a vital neutralization experiment. Thus, the antibodies production shows PLACCINE’s ability to protect against SARS-CoV-2 exposure, and cytotoxic T-cell response elicitation demonstrates the potential of the vaccine platform in eradicating infected SARS-CoV-2 cells.
The findings show Celsions’ PLACCINE DNA vaccine’s immunogenicity potential, which will offer resistance and protection against a wide range of variants through the incorporation of several viral antigens to enhance vaccine stability for storage at temperatures above 40 C and boost easer and affordable production. The company will report the findings during the International Vaccines Conference on October 19- 21, 2021. PLACCINE has been designed to enhance the extent of the immune response through targeting various antigens or a variety of mutants in the same antigen. Investors should keep an eye on CLSN.
On Thursday, CLSN stock increased 2.91% at $1.06 with more than 1.81 million shares, compared to its average volume of 1.38 million shares. The stock has moved within a range of $1.0400 – 1.0700 after opening the trade at $1.05.